Higher ustekinumab concentrations in induction are associated with better endoscopic outcomes in inflammatory bowel disease.

ABSTRACT:

Background

Evidence suggests a relationship between ustekinumab (UST) concentrations and therapeutic outcomes in inflammatory bowel disease.

Objectives

This study aimed to evaluate the association between UST concentrations during the induction phase and treatment outcomes at week 24 in patients with Crohn's disease (CD) and ulcerative colitis (UC). The primary outcome was endoscopic remission at week 24, defined as a simple endoscopic score (SES-CD) ⩽2 for CD and a Mayo endoscopic score = 0 for UC. Secondary outcomes included endoscopic response, clinical remission, and treatment persistence.

Design

This was a prospective observational study assessing clinical and endoscopic outcomes in CD and UC patients starting UST therapy.

Methods

Consecutive patients with

SUBMITTER: Serra-Ruiz X 

PROVIDER: S-EPMC12497976 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature